Synthesis of novel thiazole, pyranothiazole, thiazolo[4,5-b]pyridines and thiazolo[5′,4′:5,6] pyrano[2,3-d]pyrimidine derivatives and incorporating isoindoline-1,3-dione group

Mona A. Hosny¹, Yasser H. Zaki²*, Wafaa A. Mokbel¹ and Abdou O. Abdelhamid³*

Abstract

Background: Thiazole is a core structural motif presents in a wide range of natural products. Thiazole derivatives also have a wide range of medicinal and biological properties.

Results: The reaction of hydrazonoyl halides with 2-(1-(4-(1,3-dioxoisoindolin-2-yl)phenyl)ethylidene)hydrazine-carbothioamidein ethanol and triethylamine yielded 2-(4-(1-(2-(4-(2-Arylhydrazono)-5-s-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione and 2-(4-(1-(2-(5-(2-Arylhydrazono)-4-oxo-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione. The reaction of 2-(1-(2-(5-(2-Arylhydrazono)-4-oxo-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione with arylidenemalononitrile also yielded 5-amino-2-(1-(4-(1,3-dioxoisoindolin-2-yl)phenyl)ethylidene)hydrazino)-7-substituted-7H-pyran[2,3-d]thiazole-6-carbonitrile. The structures of the newly synthesized compound were elucidated whenever possible on the basis of elemental analysis, spectral data, and alternative synthetic routes. Three of them were evaluated against a breast cancer cell line for their antitumor activity.

Conclusions: Compound (1) has been shown to be useful in the synthesis of a new series of 1,3-thiazole, pyrano[2,3-d]thiazole and 4,5-dihydrothiazolo[4,5-b]pyridine derivatives using hydrazonoyl halides as precursors. The anticancer efficacy of compounds (9b), (9e), and (9f) against MCF-7, a breast cancer cell line, was also compared to the standard anticancer drug doxorubicin.

Keywords: Aminoacetophenone, Isobenzofuran-1, 3-dione, Thiazole, Hydrazonoyl halide, Thiazolo[4, 5-b]pyridine

Introduction

In a variety of natural products, such as vitamin B1 (thiamine) and penicillin, thiazole is a core structural motif. Thiazole derivatives also have a wide range of medicinal and biological properties, including antibacterial, antifungal [1], anti-inflammatory [2], antiviral [3], antimalarial [4], and anti-HIV activities [5]. Thiazole analogs can serve as estrogen receptor ligands [6], neuropeptides [7], and Y5 adenosine receptors [8]. They may inhibit the aggregation factor of human platelets [9], urokinase [10], and poly (ADP-ribose) polymerase-1 [11]. Furthermore, thiazoles are involved in the development of pain therapy drugs [12]. They act as fibrinogenic receptor antagonists with antithrombotic activity [13], and as new bacterial DNA gyrase B inhibitors [14]. Pyrano[2,3-d]thiazoles show a wide range of drug development applications against obesity, hyperlipidemia, atherosclerotic diseases [15, 16]. This study is a continuation of our earlier work on the synthesis of biologically active heterocycles [17–21]. The synthesis of new heterocyclic thiazole, pyranothiazole, thiazolo[4,5-b]pyridine and thiazolo[5′,4′:5,6] pyrano[2,3-d]pyrimidine derivatives is reported in this document to obtain highly effective antimicrobial and anticancer agents.
Results and discussion

Treatment of 4-aminoacetophenone with isobenzofuran-1,3-dione in a boiling acetic acid produced 2-(4-acetylphenyl)isoindoline-1,3-dione (1). Compound (1) was reacted with thiosemicarbazide (2) to afford 2-(1-(4-(1,3-dioxoisindolin-2-yl)phenyl) ethylidene) hydrazinecarbothioamide (3). The structure of compound (3) was deduced by spectral data, elemental analyses, and chemical transformation. In boiling ethanol containing triethylamine, compound (3) was further reacted with 2-oxo-N-phenylpropanehydrazoney chloride (4a) to produce a product that could be isolated by thin layer chromatography (TLC). The compound formula was determined to be: 2-4-(1-(2-(4-methyl-5-(phenyldiazeyl)thiazol-2-yl)hydrazono)ethyl)phenyl) isoindoline-1,3-dione (9a), based on its spectral data and elemental analysis. Similarly, the corresponding hydrazonoyl halides (4b–f) were reacted with compound (3) to produce 2-(4-(1-(2-(4-substituted 5-(aryldiazenyl) thiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione (9b–f) (Scheme 1). Reaction of compound (3) with ω-bromoacetophenone gave 2-(4-(1-(2-(4-phenylthiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione (10). Compound (10) has been reacted with benzenediazonium chloride in ethanolic sodium acetate solution to produce a product that is identical in all aspects (mp, mixed mp, and spectra) to compound (9d). Considering these results, the mechanism outlined in Scheme 1 seemed to be the most plausible pathway for the formation of (9) from the reaction of compound (4) or (5) with compound (3). The reaction involves the initial thiohydrazonoyl formation (8), which underwent intramolecular cyclization directly to afford (9) through elimination of a H2O molecule or through 1,3-dipolar cycloaddition of nitrile imine (5) to the C=S double bond of (3) to afford thiaidazole (7) via elimination of NH3. Structure (7) was excluded on the basis of elemental analyses, spectra data and alternative synthetic route.

However, reaction of compound (3) with ethyl 2-chloro-2-(2-phenylhydrazono)acetate (11a) in ethanol containing a catalytic amount of triethylamine afforded 2-(4-(1-(2-(4-oxo-5-(2-(4-chlorophenyl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (12a). The spectral data, elemental analyses, and alternative syntheses elucidated the structure of compound (12a). Reaction of ethyl chloroacetate with compound (3) in boiling ethanol yielded 2-(4-(1-(2-(4-oxo-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (13). Coupling of benzenediazonium chloride with (13) in a cold solution of ethanolic sodium acetate gave a product identical in all aspects (mp, mixed mp, and spectra) with compound (12a) (Scheme 2). Analogously, reaction of hydrazonoyl chlorides (11b) and (11c) with compound (3) in ethanolic triethylamine afforded 2-(4-(1-(2-(4-oxo-5-(2-(p-tolyl)hydrazono)4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione (12b) and 2-(4-(1-(2-(5-(2-(4-chlorophenyl)hydrazono)4-oxo-4,5-dihydrothiazol-2-yl)-hydrazono)ethyl)phenyl)isoindoline-1,3-dione (12c) (Scheme 2).

Ultimately, the treatment of 2-(4-(1-(2-(4-oxo-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)phenyl)isoindoline-1,3-dione (13) with the appropriate 2-(arylethylene)malononitrile (14a) and (14b) in ethanol containing a catalytic amount of piperidine afforded 5-amino-2-(1-(4-(1,3-dioxoisindolin-2-yl) phenyl)ethylidene)-hydrazinyl)-7-phenyl-7H-pyrano[3,2-d]thiazole-6-carbonitrile (15a) and 5-amino-2-(1-(4-(1,3-dioxoisindolin-2-yl)phenyl)ethylidene) hydrazinyl)-7-(thien-2-yl)-7H-pyran[2,3-d]thiazole-6-carbonitrile (15b), respectively. The corresponding structures of these compounds were elucidated by spectral data, elemental analyses, and chemical transformation. Boiling compounds (15a) and (15b) in acetic acid and ammonium acetate afforded 2-(1-(4-(1,3-dioxoisindolin-2-yl)phenyl)ethylidene)-hydrazinyl)-5-oxo-7-phenyl-4,5-dihydrothiazolo[4,5-b]pyridine-6-carbonitrile (16a) and 2-(1-(4-(1,3-dioxoisindolin-2-yl)phenyl)ethylidene)hydrazinyl)-5-oxo-7-(thien-2-yl)-4,5-dihydrothiazolo[4,5-b]pyridine-6-carbonitrile (16b), respectively (Scheme 3). The previous reaction was carried out in acetic acid containing ammonium acetate to afford products identical in all aspects (mp, mixed mp, and spectra) with (16a) and (16b) (Scheme 3).

Cytotoxicity evaluations

Through the literary survey it became clear to us that many thiazole derivatives have an excellent anti-tumor activity as shown in Fig. 1 [22, 23]. In light of this, antitumor activity was examined for a new series of thiazole compounds selected indicate that, higher concentrations may be used for more anticancer effect. The results are shown in Table 1 and Fig. 2 as follows:
The in vitro inhibitory activities of tested compounds against breast cancer cell line (MCF-7) have the following descending order: (9b) > (9e) > (9f).

Examination of the SAR leads to the following conclusions:

- For substituents in position 4 and 5 of the thiazole ring, the following descending order is the in vitro inhibitory activity of tested compounds against breast cancer cell line. The activity of thiazole (9e) is moderate.

Experimental

All of the melting points were determined using a Gallenkamp electrothermal melting point apparatus (Laim George, Calgary, AB, Canada) and, they are uncorrected.
The IR (cm\(^{-1}\)) spectra were recorded using a KBr disk on a FTIR-8201 spectrophotometer (Shimadzu, Tokyo, Japan). The \(^1\)H NMR and \(^{13}\)C NMR spectra were recorded in DMSO-d\(_6\) on a Bruker Bio Spin AG spectrometer (Bruker, Switzerland) at 400 and 100 MHz. Mass spectra were recorded at 70 eV on a Shimadzu GCMS-QP1000 EX mass spectrometer (Tokyo, Japan). Elemental analyses were conducted at the Microanalytical Center of Cairo University. All reactions were followed by TLC (silica gel, Merck, Kenilworth, NJ, USA). As reported, hydrazonoyl halides have been prepared \([24–29]\).

**Synthesis of 2-(4-Acetylphenyl)isoindoline-1,3-dione (1)**

In 10 mL acetic acid, a mixture of 4-aminoacetophenone (1.35 g, 10 mmol) and isobenzofuran-1,3-dione (1.48 g, 10 mmol) was heated for 2 h under reflux. The solid was gathered and crystallized from ethanol, with a yield of 2.54 g (97%), mp: 230–232 °C; IR (KBr, cm\(^{-1}\)): 3087 (C–H aromatic), 2963, 2893 (C–H), 1706 (C=O), 1617 (C=C); \(^1\)H-NMR (CDCl\(_3\))\(\delta\): 2.49 (s, 3H, CH\(_3\)), 6.70–6.73 (d, 2H, J=8 Hz, Ar–H), 7.99–8.00 (d, 2H, J=8 Hz, Ar–H), 8.01–8.03 (d, 2H, J=8 Hz, Ar–H), 8.17–8.19 (d, 2H, J=8 Hz, Ar–H); \(^{13}\)C-NMR (100 MHz) (DMSO-d\(_6\)) \(\delta\): 26.2, 117.4, 125.9, 129.6, 130.1, 131.5, 33.3, 134.6, 165.4, 196.3. Anal. Calcd. for C\(_{16}\)H\(_{11}\)NO\(_3\) (265.26): C, 72.45; H, 4.18; N, 5.28; found: C, 72.54; H, 4.21; N, 5.37.

**Figures**

- **Figure S1**
  A mixture of 2-(4-acetylphenyl)isoindoline-1,3-dione (1) (2.65 g, 10 mmol) and thiosemicarbazide (0.97 g, 10 mmol) in 20 mL ethanol, as well as a few drops of concentrated HCl, was heated for 30 min under reflux. The bright beige needles were gathered and recrystallized from ethanol, with a yield of 2.9 g (97.6%), mp: 250 °C; IR (KBr, cm\(^{-1}\)): 3319, 3262, 3151 (NH, NH\(_2\)), 1706 (CO), 1617 (C=N), 1174 (C=S); \(^1\)H-NMR(CDCl\(_3\))\(\delta\): 2.35 (s, 3H, CH\(_3\)), 7.47 (d, 2H, J=8 Hz, Ar–H), 7.67 (d, 2H, J=8 Hz, Ar–H), 7.83(d, 2H, J=8 Hz, Ar–H), 7.93–8.06 (m, 4H, Ar–H), 8.29 (s, br. 1H, NH); \(^{13}\)C-NMR (100 MHz) (DMSO-d\(_6\)) \(\delta\): 18.9, 123.9, 127.3, 127.5, 131.9, 133.1,
135.3, 137.7, 147.8, 167.4, 179.6. MS; m/z %: 338 (M$$^+$$, 4.3), 324 (17.6), 323 (86), 321 (44), 304 (15), 278 (24), 264 (35), 263 (83), 249 (46), 222 (44), 204 (17), 166 (27), 139 (14), 116 (17), 104 (57), 102 (24), 90 (22), 77 (30), 76 (100), 59 (17), 50 (24). Anal. Calcd. for C$_{17}$H$_{14}$N$_4$O$_2$S (338.38): C, 60.34; H, 4.17; N, 16.56; S, 9.48; found: C, 60.22; H, 4.14; N, 16.68; S, 9.52.

Synthesis of 2-(4-(1-(2-(4-Methyl-5-(phenyldiazenyl)thiazol-2-yl)-hydrazono)ethylidene)hydrazinyl)-5-oxo-7-substituted-4,5-dihydrothiazolo[4,5-b]pyridine-6-carbonitrile (16a, b)

A mixture of the appropriate hydrazonoyl halides (4a–f) (1 mmol), 2-(1-(4-(1,3-dioxoisoindolin-2-yl)phenyl)ethylidene)hydrazinecarbothioamide (3) (0.338 g, 1 mmol) in ethanol (20 mL) and triethylamine (0.15 mL, 1 mmol) was heated for 2 h under reflux. The formed solid in this way was gathered and crystallized from acetic acid. Products 9a–f were prepared together with their physical constants, and they are described as follow.

2-(4-(1-(2-(4-Methyl-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (9a) Additional file 2: Figure S2

Scarlet-red (98.3% yield); mp: 240 °C; IR (KBr, cm$^{-1}$): 3326 (NH), 1710 (CO), 1547 (C=N), 1492 (N=N); $^1$H-NMR (CDCl$_3$) $\delta$: 2.19 (s, 3H, CH$_3$), 2.35 (s, 3H, CH$_3$), 7.33–7.27 (m, 5H, Ar–H), 7.54 (d, 2H, J = 8 Hz, Ar–H), 7.68 (d, 2H, J = 8 Hz, Ar–H), 7.79 (d, 2H, J = 8 Hz, Ar–H),
Table 1 The in vitro inhibitory activity of tested compounds against breast cancer cell line expressed as IC₅₀ values (µM)

| Compound no. | MCF-7 IC₅₀ (µM) |
|--------------|-----------------|
| Doxorubicin   | 8.28            |
| 9b           | 22.04           |
| 9e           | 30.07           |
| 9f           | 35.94           |

![Figure S3](image.jpg)

Fig. 2 Cytotoxicity (IC₅₀, µM) of the synthesized compounds (9b), (9e) and (9f) against the MCF-7 breast cell line.

8.07 (d, 2H, J = 8 Hz, Ar–H), 8.11 (s, br., 1H, NH), 13C-NMR (100 MHz) (DMSO-d₆) δ: 15.7, 18.9, 114.8, 122.8, 123.9, 127.3, 127.5, 127.8, 129.7, 131.9, 133.1, 135.3, 127.7, 143.9, 147.9, 167.4, 179.6. MS; m/z %: 481(M⁺, 33), 480 (97), 479 (32), 465 (35), 447 (64), 339 (21), 375 (24), 343 (16), 288 (17), 275 (13), 263 (77), 249 (35), 222 (48), 204 (19), 166 (39), 140 (16), 105 (18), 93 (19), 77 (100), 76 (65), 51 (15). Anal. Calcd. For C₁₆H₁₉ClN₆O₂S (412.79): C, 57.47; H, 3.66%; N, 16.32; S, 6.89%; Found: C, 57.0; H, 3.66; N, 16.32; S, 6.89.

2-(4-(1-(2-(5-(4-Chlorophenyl)diazetyl)-4-methylthiazol-2-yl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (9c) Additional file 4: Figure S4

Dark orange (98.5% yield); mp: 210–240 °C; IR (KBr, cm⁻¹): 3279 (NH), 1710 (C=O), 1595 (C=N); 1H-NMR(CDCl₃) δ: 2.12 (s, 3H, CH₃), 2.56 (s, 3H, CH₃), 7.52 (d, 2H, J = 8 Hz, Ar–H), 7.56 (d, 2H, J = 8 Hz, Ar–H), 7.80 (d, 2H, J = 8 Hz, Ar–H), 7.90 (d, 2H, J = 8 Hz, Ar–H), 7.92–8.5 (m, 4H, Ar–H), 8.89 (s, br., 1H, NH); 13C-NMR (100 MHz) (DMSO-d₆) δ: 9.0, 14.3, 123.9, 127.3, 127.5, 130.2, 131.9, 133.1, 135.3, 137.7, 147.9, 179.6. MS (m/z %): 516 (M⁺, 11), 514(M⁺, 27), 247 (17), 263 (31), 249 (24), 222 (22), 166 (25), 140 (13), 139 (17), 111 (41), 104 (44), 102 (29), 90 (23), 77 (30), 76 (100), 50 (30). Anal. Calcd. For C₁₆H₁₉ClN₆O₄S (542.61): C, 61.21; H, 3.72; N, 16.32; S, 6.23; Found: C, 60.82; H, 3.57; N, 16.12; S, 6.45.

2-(4-(1-(2-(5-(4-Chlorophenyl)diazetyl)-4-methylthiazol-2-yl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (9d) Additional file 5: Figure S5

Red needles (99.5% yield); mp: 240 °C; IR (KBr, cm⁻¹): 3065 (NH), 1709 (C=O), 1598 (C=N); 1H-NMR(CDCl₃) δ: 2.38 (s, 3H, CH₃), 7.03–8.29 (m, 18 H, Ar–H) and 10.12 (s, 1H, NH). MS (m/z %): 542 (M⁺, 45), 514 (20), 438 (24), 263 (49), 249 (32), 222 (29), 166 (27), 105 (18%), 104 (48%), 77 (100), 76 (56), 51 (15). Anal. Calcd. For C₁₆H₁₉ClN₆O₄S (480.54): C, 64.98; H, 4.20; N, 17.49; S, 6.67; Found: C, 65.10; H, 4.32; N, 17.52; S, 6.79.

2-(4-(1-(2-(5-(4-Chlorophenyl)diazetyl)-4-methylthiazol-2-yl)hydrazono)ethyl)phenyl)-isoindoline-1,3-dione (9g) Additional file 6: Figure S6

Yellow needles (86% yield); mp: 230 °C; IR (KBr, cm⁻¹): 3276 (NH), 1707 (C=O), 1609 (C=N); 1H-NMR(CDCl₃) δ: 2.38 (s, 3H, CH₃), 6.82 (s, 1H, thienyl-H4), 7.02–7.17 (m, 2H, thienyl H3, H5), 7.37 (d, 2H, J = 8 Hz, Ar–H), 7.52 (d, 2H, J = 8 Hz, Ar–H), 7.80 (d, 2H, J = 8 Hz, Ar–H), 7.97–8.01 (m, 7H, Ar–H), 10.14 (s, 1H, NH); 13C-NMR (100 MHz) (DMSO-d₆) δ: 14.3, 91.4, 112.7, 112.9, 117.5, 121.2, 122.3, 123.9, 126.4, 127.4, 127.5, 128.7, 129.3, 129.5, 129.6, 130.0, 131.8, 133.0, 134.0, 135.3, 137.6.
2-(4-((1-(2-(4-(Naphthalen-2-yl)-5-(phenyl diazenyl)thiazol-2-yl)hydrazono)ethyl)-phenyl)isoindoline-1,3-dione (9f) Additional file 7: Figure S7
Red needles (99.5% yield); mp: 248 °C; IR (KBr, cm⁻¹): 3279 (NH), 1708 (CO), 1595 (C=N); ¹H-NMR (CDCl₃) δ: 2.27 (s, 3H, CH₃), 7.40–7.50 (m, 3H, Ar–H), 7.54 (d, 2H, J=8 Hz, Ar–H), 8.16 (d, 2H, J=8 Hz, Ar–H), 8.76 (s, 1H, Ar–H), 9.74 (s, br., 1H, NH). Anal. Calcd. For C₂₉H₂₀N₆O₂S (548.64) C, 63.55; H, 3.78; N, 15.32; S, 11.69. Found: C, 63.49; H, 3.67; N, 15.29; S, 11.74.

Synthesis of 2-(4-(1-(2-(4-phenylthiazol-2-yl)hydrazono)-ethyl)-phenyl)isoindoline-1,3-dione (10) Additional file 8: Figure S8
In 10 mL ethanol, a mixture of compound (1) (0.26 g, 10 mmol) and phenacylbromide (1.99 g, 10 mmol) was heated for 2 h under reflux. A yellow ppt. has been gathered and recrystallized from methanol (97% yield); mp: 260–262 °C; IR (KBr, cm⁻¹): 3067 (NH), 1714 (C=O), 1592 (C=N), 1508 (C=C); ¹H-NMR (CDCl₃) δ: 2.35 (s, 3H, CH₃), 7.47–7.49 (m, 3H, Ar–H), 7.54 (d, 2H, J=8 Hz, Ar–H), 8.16 (d, 2H, J=8 Hz, Ar–H), 8.76 (s, 1H, Ar–H), 9.74 (s, br., 1H, NH). Anal. Calcd. For C₂₅H₁₇ClN₆O₃S (516.96) C, 58.08; H, 3.31; N, 16.26; S, 6.35. Found: C, 57.24; H, 3.01; N, 16.12; S, 6.30.

Synthesis of 2-(4-(1-(2-(5-(2-(4-Chlorophenyl)hydrazono)-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)-phenyl)isoindoline-1,3-dione (12b) Additional file 10: Figure S10
Dark yellow needles, recrystallized from methanol (98.3% yield); mp: 210–250 °C; IR (KBr, cm⁻¹): 3276 (NH), 1709 (CO), 1597 (C=N); ¹H-NMR (CDCl₃) δ: 2.27 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 7.47 (d, 2H, J=8 Hz, Ar–H), 7.62 (d, 2H, J=8 Hz, Ar–H), 7.91–8.11 (m, 8H, Ar–H), 10.28 (s, br., 1H, NH), 10.56 (s, br., 1H, NH). Anal. Calcd. For C₂₅H₁₇ClN₆O₃S (516.96) C, 58.08; H, 3.31; N, 16.26; S, 6.35. Found: C, 57.24; H, 3.01; N, 16.12; S, 6.30.

Synthesis of 2-(4-(1-(2-(5-(2-Chlorophenyl)hydrazono)-4-oxo-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)-phenyl)isoindoline-1,3-diones (12a–c)
In an ice bath, a mixture of compound (13) (0.38 g, 1 mmol) and sodium acetate trihydrate (0.138 g, 1 mmol) cooled to 0–5 °C in 20 mL ethanol. Appropriate quantities of arenediazonium chloride [prepared by diazotizing replaced amines (1 mmol) dissolved in hydrochloric acid (0.3 mL, 6 M) with sodium nitrite solution (0.07 g, 1 mmol) in H₂O (2 mL)] were added in portion to the previous mixture while stirring. After complete addition, the reaction mixture was stirred in an ice bath for another 2 h. The yellow solid has been filtered off, washed with H₂O, and finally recrystallized from ethanol, to give (12a–c).

2-(4-(1-(2-(4-Oxo-5-(2-phenylhydrazono)-4,5-dihydrothiazol-2-yl)hydrazono)ethyl)-phenyl)isoindoline-1,3-dione (12a) Additional file 9: Figure S9
Yellow solid (98.3% yield); mp: 230–232 °C; IR (KBr, cm⁻¹): 3279 (NH), 1708 (CO), 1595 (C=N); ¹H-NMR (CDCl₃) δ: 2.35 (s, 3H, CH₃), 7.47–7.49 (m, 3H, Ar–H), 7.90–8.06 (m, 10H, Ar–H), 10.31 (s, br., 1H, NH), 10.54 (s, br., 1H, NH). Anal. Calcd. For C₂₅H₁₇ClN₆O₃S (516.96) C, 58.08; H, 3.31; N, 16.12; S, 6.35. Found: C, 57.24; H, 3.01; N, 16.12; S, 6.30.
from ethanol to give a bright yellowish needle (96.4%, yield), mp: 258 °C; IR (KBr, cm⁻¹): 3399, 3320, 3263(NH, NH₂), 3.9 (s, 2H, Ar–CH₂), 7.47–7.49 (m, 2H, Ar–H), 7.90–8.06 (m, 6H, Ar–H), 9.36 (s, br., 1H, NH); 1³C-NMR (100 MHz) (DMSO-d₆): δ 14.3, 16.0, 115.9, 125.8, 128.5, 131.8, 134.7, 137.3, 139.7, 150.9, 164.0, 182.7. MS (m/z %): 378 (M⁺, 17), 249 (15), 222 (13), 104 (27), 76 (100), 60 (54), 59 (13). Anal. Calcd. For C₁₉H₁₇N₅O₃S₂ (538.60) C, 60.21; H, 3.37; N, 15.60; O, 18.8, 0.7. Found: C, 60.02; H, 3.25; N, 15.84; S, 12.10.

Synthesis of 7-aryl-2-(2-(1-(4-(1,3-dioxoisooindolin-2-yl)phenyl)ethylidene)-hydrazinyl)-5-oxo-4,5-dihydrothiazolo-[4,5-b]pyridine-6-carbonitrile (16a) and (16b)
A mixture of the appropriate compound (15a) or (15b) and ammonium acetate (0.53 g, 1 mmol) was heated for 2 h in acetic acid (15 mL) under reflux. To obtain (16a) and (16b), the solid was collected and recrystallized from methanol.

2-(2-(1-(4-(1,3-Dioxoisooindolin-2-yl)phenyl)ethylidene)hydrazinyl)-5-oxo-7-phenyl-4,5-dihydrothiazolo[4,5-b]pyridine-6-carbonitrile (16a)
Beige needles (96.4%, yield); mp: 265 °C; IR (KBr, cm⁻¹): 3265 (NH), 2200 (CN), 1706 (C=O), 1617(C=N). ¹H-NMR (CDCl₃) δ: 2.35 (s, 3H, CH₃), 7.25–7.29 (t, 1H, J = 8 Hz, Ar–H), 7.71–8.01 (m, 9H, Ar-H and NH), and 79.4 (s, br. 1H, NH); ¹³C-NMR (100 MHz) (DMSO-d₆): δ 14.2(CH₃), 86.1, 95.4, 115.4, 116.0, 125.8, 127.2, 128.8, 130.1, 130.7, 131.4, 134.6, 137.8, 138.1, 139.3, 145.4, 150.3, 150.5, 152.7, 161.4, 168.5, 171.2. MS (m/z %): 530 (M⁺, 0.7), 338 (64), 323 (8), 263 (85), 249 (45), 222 (38), 204 (13), 106 (22), 76 (100), 60 (54), 59 (13). Anal. Calcd. For C₂₉H₁₈N₆O₃S₂ (530.56), C, 65.65; H, 3.42; N, 15.84; S, 6.04 Found: C, 65.55; H, 3.24; N, 15.65; S, 6.12.

Alternative synthesis of (16a) and (16b)
In acetic acid (25 mL), equimolar amounts of (15a) or (15b), ammonium acetate, and arylidenemalonitrile were heated for 4 h under reflux. The reaction mixture was left at room temperature to cool. The solid formed...
was filtered off, dried and recrystallized from methanol to obtain an identical product with (16a) and (16b) in all aspects of mp, mixed mp, and spectra.

**Evaluation of the antitumor activity using viability assay**

The carcinoma cell line utilized during this study, MCF-7, was gotten from the American Kind Culture Group (ATCC, Minnesota, USA). RPMI-1640 environment was utilized for culturing and keeping of the human tumor cell lines [30]. The medium was supplied in a powder form. 10.4 Gram powder and 2 g NaHCO₃ in 1 L distilled H₂O are dissolved to prepare the working solution. Then, in the Melibor bacteria filter (0.22 μm), the medium was sterilized by filtration. The refrigerator was used at 0–4 °C to maintain the prepared medium. The medium was heated at 37 °C in a water bath and supplemented with 1% penicillin streptomycin and 10% of fetal bovine serum before use. Through the use of the sulforhodamine-B (SRB) assay [31] the cytotoxicity assay was performed. SRB is aminoxanthrene dye with two SO₂H groups. It is a protein patches that binds to the amino groups of intracellular proteins under slightly acidic conditions to supply a sensitive indicator of cellular protein content. In MCF-7 cells, cytotoxicity was tested for all compounds. At the National Cancer Institute, Cairo, Egypt, by serial subculturing all experiments and data related to the assessment of cellular cytotoxicity were conducted. For the cytotoxicity assay, cells were seeded in 96-well microliter plates at an initial concentration of 3 × 10³ cells/well in 150 μL of fresh medium and left to attach to the plates for 24 h. At variable concentrations of 0, 5, 12.5, 25 and 50 μg/mL, the drug was added. Three wells were used for every concentration of drugs and the plates were incubated for 48 h. The cells were fixed by adding 50 μL of cold trichloro acetic acid (10% final concentration) at 4 °C for 1 h. The plates were therefore washed with 1% acetic acid at room temperature for 30 min. With 1% acetic acid and dried air, the plates were washed. 100 μL/well of 10 M Tris base (pH 10.5) solubilized the dye. With an ELISA microplate reader (Sunrise Tecan Reader, Tecan, Germany), the optical density (O.D.) of each well was measured spectrophotometrically at 570 nm. The mean absorption of the background was automatically subtracted and the mean values were calculated for each concentration of drugs. Three times the experiment was repeated. The cell survival percentage was calculated as follows: Fraction surviving = O.D. (treated cells)/O.D. (control cells). The values of inhibitory concentration (IC₅₀) (resveratrol concentrations required to inhibit cell growth by 50%) have also been calculated. The relationship between the surviving cells and the concentration of the drug was plotted after treatment with the specified compound to obtain the survival curve of each tumor cell line. The IC₅₀, The concentration required by 50% of intact cells to cause toxic effects, was estimated at each concentration from graphical plots of the dose response curve.

**Conclusions**

Compound 1 was useful for synthesizing a new series of 1,3-thiazole, pyrano[2,3-d]thiazole and 4,5-dihydrothiazolo[4,5-b]pyridine derivatives using hydrazonoyl halides as precursors. The anticancer effectiveness of compounds 9b, 9e, and 9f against the MCF-7, breast cancer cell line, was also compared with that of the standard anticancer drug doxorubicin.

**Additional files**

Additional file 1: Figure S1. The ¹H NMR and ¹³C NMR of compound (3).
Additional file 2: Figure S2. The ¹H NMR and ¹³C NMR of compound (9a).
Additional file 3: Figure S3. The ¹H NMR and ¹³C NMR of compound (9b).
Additional file 4: Figure S4. The ¹H NMR and ¹³C NMR of compound (9c).
Additional file 5: Figure S5. The ¹H NMR and ¹³C NMR of compound (9d).
Additional file 6: Figure S6. The ¹H NMR and ¹³C NMR of compound (9e).
Additional file 7: Figure S7. The ¹H NMR and ¹³C NMR of compound (9f).
Additional file 8: Figure S8. The ¹H NMR and ¹³C NMR of compound (10).
Additional file 9: Figure S9. The ¹H NMR and ¹³C NMR of compound (12a).
Additional file 10: Figure S10. The ¹H NMR and ¹³C NMR of compound (12b).
Additional file 11: Figure S11. The ¹H NMR and ¹³C NMR of compound (12c).
Additional file 12: Figure S12. The ¹H NMR of compound (13).
Additional file 13: Figure S13. The ¹H NMR and ¹³C NMR of compound (15a).
Additional file 14: Figure S14. The ¹H NMR and ¹³C NMR of compound (15b).

**Abbreviations**

MCF-7: the breast cancer cell line; IC₅₀: the concentration required to cause toxic effects in 50% of intact cells; O.D.: the optical density; ATCC: the American Type Culture Collection; mp: melting point; Mw: molecular weight.

**Authors’ contributions**

AOA, YHZ, MAH, and WAM designed the research, performed the research, analyzed the data, wrote the paper the final manuscript. All authors read and approved the final manuscript.
Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets are fully available without restriction at the author’s institutions.

Funding
The datasets are fully available without restriction at the author’s institutions.

Availability of data and materials
The datasets are fully available without restriction at the author’s institutions.

References
1. Bharti SK, Nath G, Tilak R, Singh S (2010) Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2, 4-disubstituted thiazole ring. Eur J Med Chem 45(2):651–660
2. Yang BV, Weinstein DS, Doweyko AM, Mckay L, Holloway DA (2010) Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated guanylcyclitide receptor antagonists. J Med Chem 53(23):8241–8251
3. Spector F, Liang L, Giordano H, Sivaraja M, Peterson M (1998) Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL3-UL5UL2 complex. J Virol 72(9):6979–6987
4. González Cabrera D, Douelle F, Feng-T-S, Nichinda AT, Younis Y, White KL, Wu Q, Ryan E, Burrows JW, Waterston D (2011) Novel orally active antimarial thiazoles. J Med Chem 54(21):7713–7719
5. Bell FW, Cantrell AS, Hoegberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM Jr (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogues. J Med Chem 38(25):4929–4936
6. Fink BE, Mortensen DS, Staufer SR, Aron ZD, Poppavin M (1999) Novel structural templates for estrogen-receptor ligands and prospects for combinational synthesis of estrogens. Chem Biol 6(4):205–219
7. Biagetti M, Leslie CP, Mazzali A, Serti C, Pizz DA, Bentley J, Genski T, Di Fabio R, Zonzini L, Fabio R, Zonzini L, Caberlotto L (2010) Synthesis and structure-activity relationship of N,N'-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1, 3-thiazoles and 5-arylazothiazoles. J Chem Res Synopses 9:532–533
8. Biagetti M, Leslie CP, Mazzali A, Serti C, Pizz DA, Bentley J, Genski T, Di Fabio R, Zonzini L, Fabio R, Zonzini L, Caberlotto L (2010) Synthesis and structure-activity relationship of N,N'-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1, 3-thiazoles and 5-arylazothiazoles. J Chem Res Synopses 9:532–533
9. Bhoga U (2007) Novel synthetic approach to N-aryl-4-(3-pyridyl) thiazol-2-amine and analogues using HVMCA-41 as a catalyst, and their biological evaluation as human platelet aggregation inhibitors. Eur J Med Chem 42(8):1144–1150
10. Wilson CJ, Illig CR, Subasinghe N, Hoffman JR, Rudolph MJ, Soll R, Molloy CJ, Bone R, Green D, Randall T (2001) Synthesis of thiophene-2-carboxamides containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors. Bioorg Med Chem Lett 11(7):915–918
11. Zhang W-T, Ruan J-L, Wu P F, Jiang F-C, Zhang L N, Fang W, Chen X-L, Wang Y, Cao B-S, Chen G-Y (2009) Design, synthesis, and cytotoxic protec-